A Prospective Study Evaluating COVID-19 Vaccine Immunogenicity in Organ Transplant Recipients (the PREVenT-COVID study) – Pediatric Arm
Children who received organ transplant are eligible to receive COVID-19 vaccine when it is licensed for their age group. People with organ transplant may have different immune response to COVID-19 vaccine compared to their "healthy" peers. This study will assess immune response to COVID-19 vaccine in BC children living with organ transplant and see how it compares to immune response in healthy children of similar age. It will also collect data about vaccine safety in children with organ transplant through systematically recording adverse events and monitoring for potential organ rejection. This pediatric study is part of a the larger National PREVenT-COVID study, led by researchers at the University Hospital Network (UHN) in Toronto and in collaboration with the Canadian Donation and Transplantation Research Program (CDTRP), that is studying the safety and immunogenicity of COVID-19 vaccines in adult solid organ transplant patients and patients who have received stem cell transplants.
This is a multi-center pediatric study being conducted by Dr. Hana Mitchell's research team at BC Children's Hospital Research Institute. Dr. Kumar is the Principle Investigator for the national multi-center study, which includes both the adult and pediatric arms of the study.
- Project Status
Status: Active, data collection ongoing
Study Start Date: November 19, 2021
Study End Date: March 30, 2023
Study Enrollment Status: Active
Start Date: November 19, 2021
End Date: March 30, 2023
- Project Team
Research Team Members
Candice Wiedman, Research Assistant
Hyunwoong Chae, Research Assistant
Monica Ho, Research Coordinator
- Enrollment Eligibility Criteria
- Children ≤18 years of age who are or will be eligible to receive an authorized COVID-19 vaccine.
- For those currently eligible - they are planning to receive their first dose of COVID-19 vaccine within the next month OR they have already been vaccinated with one or more doses and plan on receiving all the doses recommended for them.
- At BCCH Potential participants who are SOT recipients must also have previously consented to the BCCH Biobanking Registry (H17-06240) in order to be eligible OR are willing to consent into the BCCH Biobanking registry at the time of enrolling into this current study.
- At BCCH potential participants have to be able to come to BCCH for all the study-related blood draws
- Additional criteria for healthy controls. No known immuno-compromising conditions or on-going use of prescription medications leading to impaired immune response (inhaled corticosteroids are not considered immune suppressive for the purpose of this study)
For more information, or if you're interested in participating, please email Candice.Wiedman@bcchr.ca.